IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company focused on the development and commercialization of novel implantable Sacral Neuromodulation (“SNM”) devices for the treatment of urinary and bowel dysfunction, today announced that members of the management team will participate in the following upcoming investor events:
- Management is scheduled to present at the Barclays Global Healthcare Conference, Thursday, March 14, at 9:30 am ET in Miami Beach, FL, and will be available for one-on-one meetings.
- Management will also be available for one-on-one meetings at the Morgan Stanley Healthcare Corporate Access Day, Tuesday, March 19, in Boston.
To access the live webcast of the presentation at the Barclays Global Healthcare Conference, please visit the Events & Presentations page of the Investors section of the Company's website at ir.axonicsmodulation.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will be archived on the Company's website for 90 days.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, CA, is focused on the development and commercialization of a novel implantable SNM system for patients with urinary and bowel dysfunction. The Axonics r-SNM® System is the first rechargeable Sacral Neuromodulation system approved for sale in Europe, Canada and Australia, and the first SNM system to gain CE mark for full-body MRI conditional labeling. Premarket Approval (PMA) for the r-SNM System is currently pending with the U.S. FDA. For more information, visit the Company’s website at www.axonicsmodulation.com.